Primary Care

Heart Failure Diagnostic and Treatment Pathways

Edited and updated in July 2024 by NHS Sussex ICB – Heart Failure Steering Group in collaboration with Health Innovation Kent Surrey Sussex – CVD Team Designed in 2020 by Professor Ahmet Fuat MBChB PhD FRCGP FRCP (London) FRCP (Edinburgh) FPCCS PGDiP Cardiology. With thanks to Professor Jerry Murphy and the Darlington Heart Failure service. Endorsed by British Heart Foundation (BHF), Primary Care Cardiovascular Society (PCCS), Pumping Marvellous Foundation, Arrhythmia Alliance, AF Association Contact: Jen Bayly, Health Innovation KSS, Clinical Project Advisor – CVD Prevention:jennifer.bayly@nhs.net Created November 2020. Updated May <u>2021 and July 2024. Review 2026</u>







Primary Care Cardiovascular Society Empowering primary care to deliver the best in cardiovascular health







Introduction

Heart failure affects over a million people across the UK with 200,000 new diagnoses every year. It is a life-limiting condition that too often causes emergency hospital admissions, poor quality of life and ultimately early death. It is possible to live well with heart failure and our Heart Failure pathways have been standardised for use in Primary Care services to facilitate referrals to diagnostic and heart failure treatment services.

Early diagnosis of people with heart failure with prompt access to integrated services and specialist care can help to cut emergency admissions, improve quality of life and give people the opportunity to live well and longer.

However, it is estimated that:

- there are a further 400,000 people with heart failure who are currently undetected, undiagnosed, and consequently missing out on life preserving treatment
- 80% of heart failure is diagnosed in hospital yet 40% of people had symptoms that should have triggered an earlier assessment in Primary Care in the months prior to hospital admission.

This document is a consolidation of the heart failure diagnostic and treatment pathways:

- If suspected unconfirmed heart failure use the <u>diagnostic pathway</u>
- If heart failure already confirmed use the treatment pathway for heart failure phenotype. Recent advances in the pharmacological treatment of heart failure have expanded the options for patients. See treatment pathways, which are in line with ESC guidelines.
 - » HFpEF (heart failure with preserved ejection fraction: EF ≥50%)
 - » HFmrEF (heart failure with mildly reduced ejection fraction: EF 41-49%)
 - » HFrEF (heart failure with reduced ejection fraction: EF ≤40%)

If managing a patient for an exacerbation of known heart failure, consider undertaking ECG, relevant bloods and referral back to the heart failure service/nurse where it meets their criteria or otherwise hospital or community heart failure specialist clinic.

Always think FRAILTY First (appendix 1)

Many heart failure patients will be living with frailty. Consider risk of fall /fracture / electrolyte disturbances. Investigation and management must always be individualised taking into account frailty, palliative and end of life considerations and the patient's wishes.

Index

- 4. Abbreviations, Definitions and Coding
- 6. Suspected new diagnosis of heart failure in Primary Care
- 7. Expected treatment pathway for HFpEF (EF \geq 50%)
- 8. Expected treatment pathway for HFmrEF (EF 41% 49%)
- 9. Expected treatment pathway for HFrEF (EF \leq 40%)
- 10. Expected Primary Care management of decompensated Chronic Heart Failure aiming to avoid hospital admission

11. Appendices

- Appendix 1: Considering Frailty First in HF Management
- Appendix 2: Community Heart Failure Service Pathway (Example pathway)
- Appendix 3: Specialist re-assessment and possible treatment options for HFrEF
- Top tips for reviewing patients with chronic heart failure in a virtual consultation
- Top tips for heart failure specialist nurses when reviewing patients with chronic heart failure in a virtual consultation
- Primary Care Heart Failure Patient Advice Sheet
- Heart Failure Patient Self Management
- Resources for Clinicians and Patients

Abbreviations, Definitions and Coding

Definition of Heart Failure

European Society of Cardiology: Heart Failure guideline update 2023.

Type of heart fail	ure	HFrEF	HFmrEF	HFpEF	
Criteria	1	Symptom +/- signs			
	2	$LVEF \le 40\%$	LVEF 41-49%	LVEF≥ 50%	
	3			Objective evidence of cardiac structural and/or functional abnormalities consistent with LV diastolic dysfunction /raised LV filling pressures, including raised natriuretic peptides	

Abbreviations used


- EFejection fraction
- LVleft ventricular
- HFrEF.....heart failure with reduced ejection fraction
- HFmrEF...heart failure with mildly reduced ejection fraction
- HFpEFheart failure with preserved ejection fraction
- ACEIangiotensin converting enzyme inhibitor
- ARB.....angiotensin receptor blocker
- ARNI......angiotensin receptor/ neprilysin inhibitor

- BBbeta-blocker
- MRAmineralocorticoid receptor antagonist
- SGLT2i....sodium glucose cotransporter-2 inhibitor
- CRT-P.....cardiac resynchronisation therapy - pacing
- **CRT-D**cardiac resynchronisation therapy pacing and defibrillator
- ICDimplantable cardioverter-defilbrillator
- CKD.....chronic kidney disease
- IHDischaemic heart disease

Primary Care Coding


HFrEF (HF with EF \leq 40%)* AND echo shows LVSD HFmrEF (HF with EF 41-49%) HFpEF (HF with EF \geq 50%) SNOMED: 703272007 SNOMED: 407596008 SNOMED: 788950000 SNOMED :446221000 *patients with an original HFrEF diagnosis with an improved ejection fraction – i.e. more recent echo with EF>40% due to optimisation should still be considered HFrEF as per original diagnosis and must remain on their prognostic medications.






British Society For Heart Failure. Think Heart Failure (infographic) 25in25 Collaborative https://www.bsh.org.uk/25in25

Suspected new diagnosis of heart failure in Primary Care




Expected treatment pathway for HFpEF (EF \ge 50%)

(taking into account frailty, palliative/end of life considerations and the patient's wishes) See appendix 1 Frailty First guidance.



Expected treatment pathway for HFmrEF (EF 41% – 49%)

(taking into account frailty, palliative/end of life considerations and the patient's wishes) See appendix 1 Frailty First guidance.



move to heart failure review for HFmrEF (including U&E at least 6 monthly).

Expected treatment pathway for HFrEF (EF \leq 40%)

(taking into account frailty, palliative/end of life considerations and the patient's wishes) See appendix 1 Frailty First guidance.

Diuretics if fluid retention (dynamic dosing up or down). ACEi or ARB * or ARNI & BB licensed for heart failure (bisoprolol/carvedilol/nebivolol) & MRA (spironolactone or eplerenone) &

SGLT2i : dapagliflozin or empagliflozin

There is no set order for introduction of these medicines however, aim to introduce all four classes early after diagnosis.

- ACEi/ARB/ARNI should be titrated to maximum tolerated dose.
- BB should be titrated to maximum tolerated dose.
- Optimisation of medicines may be managed by Primary Care with support from HF Specialist services for advice and guidance if required.
- Seek advice and guidance from HF Specialist services to make **urgent referral** if complex, unstable, or at risk of hospital admission.

*ARB only if ACEi intolerant **ARNI if recommended by HF team/cardiology Remember to check U&Es 1-2 weeks after initiation or dose titration of ACEi, ARB, ARNI or MRA

If patient still symptomatic despite **OPTIMISED** ACEi/ARB/ARNI, BB, MRA, SGLTi seek further advice from HF Specialist team as other specialist treatments may be indicated.

This may include additional/alternative medical therapy or to be considered for device (CRT-P, CRT-D or ICD)



Follow up in Primary Care

Undertake 6/12 review as per NICE guidance.

Adjust diuretics as per clinical status. Ensure medicines titrated to maximum tolerated doses Involve palliative care as required

Expected Primary Care management of decompensated Chronic Heart Failure aiming to avoid hospital admission

Confirm previous diagnosis of HF and what type (HFrEF, HFmrEF, HFpEF) with echo report.

 $\mathbf{\Lambda}$

Management of decompensated heart failure. Check U&E's, FBC and ECG to try and identify cause of decompensation and manage accordingly.

V

Primary Care to adjust loop diuretic as appropriate, while seeking advice from HF Specialist team. Aiming for admission avoidance but the HF nurse has access to specialist care through HF MDT if required to escalate treatment in the community with a thiazide diuretic or admit / attend for IV diuretics / Virtual ward bed.

 \mathbf{V}

 $\mathbf{\Lambda}$

Provide patient with information: Give patient advice sheet, advise patient to obtain weighing scales and <u>blood pressure monitor</u> to record daily weights, BP and Pulse.

Refer to HF Specialist Team:

If patient requires specialist HF assessment. Referral should include, where available:

- Copy of latest Echo results confirming Heart Failure
- Current medication list and any recent medication changes
- Blood results
- ECG.

Also GP to telephone HF Specialist Service to discuss referral if patient at risk of emergency hospital admission.

What types of support the HF Service will offer: see also CHFNS pathway Appendix 1

 \mathbf{V}

- Monitoring & Medicines management as per NICE guidance
- Complex diuretic management.
- Referral to appropriate agencies / MDT / services
- Liaise with Consultant-led Heart Failure
 MDT for specialist advice
- Consideration for further interventions
- Consideration for palliative care services

To note – GP to check referral criteria for local Community HF nursing service if commissioned.

10

Primary Care Heart Failure Diagnostic and Treatment Pathways

Appendices

Appendix 1: Considering Frailty First in HF Management

FRAILTY is an altered biophysiological state causing depleted physiological reserves in multiple bodily systems, best considered as a long -term condition in its own right. It is a strong predictor of adverse outcomes, long term disability, risks of unplanned hospitalisation and reduced life expectancy and is the commonest primary cause or contributory cause, of all expected deaths.

Frailty is very common in adults with

heart failure – not only in older age groups (age \geq 65), as it is driven by the severity of other long-term conditions. Overall, 65% of all people with heart failure will have coexistent frailty (45-50% in HFrEF; >90% in those with HFpEF). It is important to identify & consider frailty first, in all patients with HF and consider the impact of frailty - reduced quality of life with increased risk of avoidable iatrogenic harms and premature mortality.

Heart failure medications are frequently less well tolerated in frailty. These medicines, which lower blood pressure and/or heart rate, diuretics and all types of medicines with an impact on the kidney carry much higher risk of causing harms such as falls, fractures and head injuries, AKI, electrolyte disturbance and delirium. This can lead to preventable recurrent and/or overly prolonged unplanned hospitalisations, with consequent very high in year mortality risks for persons with heart failure and frailty.

1. Screen for Clinical Frailty in all Adults with heart failure:

- a) Undertake diagnosis and staging of frailty using the <u>Clinical Frailty Score</u> (CFS, also known as Rockwood score) for:
 - » all patients \geq 65 years of age (CFS is not validated for patients under age 65)
 - any aged adult with a confirmed diagnosis of dementia. (CFS is validated for all dementia patients)
- b) Adults of any age with evidence of a possible frailty syndrome -signs of persistent mobility decline/falls, cognitive impairment, incontinence of bladder or bowels; known daily functional limitations in ADLs, or experiencing frequent side effects from prescribed medications
- c) In younger patients aged < 65 (without a dementia diagnosis) dynamic mobility/ gait speed tools such as <u>Timed Get Up and Go Test</u> can quickly detect either mild frailty, moderate frailty or severe frailty

2. "Frailty Aware" HF Management decisions

If frailty is detected (i.e. age \geq 65 with a Clinical Frailty Score \geq 4 or aged < 65 with mild/ moderate/severe frailty) always adopt & follow an individualised management approach, particularly when considering investigations, place of care, prescribing & dosing decisions for any HF medications:

- Assess for falls risk (history of recent falls or prior recurrent falls/or fear of falling)
- Assess for postural hypotension in all high-risk groups [in those with any level of frailty of any age/any aged over 80/those with co-existent diabetes] by performing a lying & standing blood pressure (BP). Management decisions to be guided by standing BP readings.
- Consider the need to reduce or stop any medications that can lower BP (including diuretics if euvolemic, nitrates and calcium channel blockers if no chest pain etc.)/ or HR, if there is significant risk of falls with evidence of symptomatic postural hypotension. Review after medication changes and further adjust if required.
- Avoid lowering BP < 130/65 or HR < 60 in severe /very severe stages of frailty
- Consider **risks of persistent problematic U+E disturbance**, especially where there is history of, or higher risk of Na/K instability/previous history of or higher risk of AKI.
- Consider any other negative impacts on **quality of life**/other risks such as delirium, incontinence.
- **Consider "what matters most"** to the individual and what they view as most important with respect to quality of life, their personal goals, their functional independence, any personal views they may have on treatment burden (including any burden from requiring more frequent clinical monitoring, such as blood tests).

3. Timely End of Life Care Discussions and Anticipatory Care

Frailty, is an independent poor prognostic indicator, especially in the context of heart failure.

Follow best practice frailty recommendations +/or National Ambitions of Palliative & End of Life Care Guidance for identifying EOL proactive indicators (either HF specific or general indicators) that could identify persons deemed more likely to be nearing End of Life (within last year of life) stages.[As per GMC definitions of End of life; Gold Standard Framework Proactive Indicator Guidance <u>GSF PIG</u> or Supportive Palliative Indicators Clinical Tool <u>SPICT</u>)] whether a person has Frailty or not.

Consider early Advance Care Planning (ACP) personalised goals of care discussions, given the far more uncertain and unpredictable terminal illness disease trajectory of heart failure.

4. Personalised Care with Patient empowered Shared Decision Making throughout

Patients should always be supported to make well informed decisions considering & respecting their own choices & preferred priorities or goals of care.

Always follow **Personalisation & Shared Decision Making (SDM)** best practice principles.

Risks of harms versus possible benefits from potential treatment options should be clearly explored with patients in an open, clear, honest, balanced and realistic way, that is applicable to each person and their unique circumstances. Always discussing where there may be greater risks with lower likelihood of or greater uncertainty of sustainable benefits of HF specific medications due to the persons frailty, to help support patients to make fully informed decisions. <u>https://gpevidence.org</u>]

Additional resources

- Medication in the Frailest Adults
- Polypharmacy Review in Patients Living with Moderate to Severe Frailty
- Addressing Palliative and End of Life Care Needs for People Living with Heart Failure 2023
- Holistic approach to drug therapy in a patient with heart failure

Acknowledgements (appendix 1) on behalf of the Primary Care Cardiovascular Society:

Dr Sarah Zaidi: GP and Clinical Frailty lead NHSE East of England

Dr Jim Moore: GPSI Cardiology and National Primary Care Workstream Co-lead Cardiac Transformation Plan NHSE Professor Raj Thakkar: GPSI and National Primary Care Workstream Co-lead Cardiac Transformation Plan NHSE Alison Warren: Consultant Pharmacist Cardiology Sussex ICB

Appendix 2: Community Heart Failure Service Pathway

(Example pathway)

HEART FAILURE DIAC							
Refer to Community Heart Failure Service Referral should include:							
Copy of latest Echo repo		Heart Failure					
 Current medication list and any recent medication 	n changes •	Blood results • Clinical Frailty Score.					
Tel: Email:							
*GP to also telephone HF Nurse to discuss referral if patient at	risk of emerg	ency hospital admission.					
Urgent referrals	Non-urgent referrals						
Telephone contact within 1 working day and home or clinic rev 2-10 working days*	view within	Telephone contact and clinical assessment review from a CHFNS within 4 weeks*					
• Patients in an exacerbation of heart failure.		 Stable patients requiring titration of evidence-based medication as per NICE guidance for heart failure. 					
 Recent hospital admission / discharge with primary diagnos heart failure. 	sis of						
In need of specific heart failure palliative care management	if required	Patients requiring education and guidance with self management strategies					
•		•					
Patients then become part of the active	heart failure	specialist service caseload					
•		•					
Unstable	Stable						
Home review within 2 working days*	Optimised on evidenced based heart failure medication						
Patient in exacerbation or high risk of exacerbation	Perso	nalised care plan in place					
 Patient in exacerbation or high risk of exacerbation Recent hospital discharge 	• No ex	nalised care plan in place acerbations of heart failure or medication					
	• No ex	nalised care plan in place					
	• No ex chang	nalised care plan in place acerbations of heart failure or medication ges within the past 3 months					
 Recent hospital discharge Monitoring & Medicines management as per NICE 	No ex chang HF Nurs	nalised care plan in place accerbations of heart failure or medication ges within the past 3 months e will refer back to GP / practice nurse for					
 Recent hospital discharge Monitoring & Medicines management as per NICE guidance 	No ex chang HF Nurs	nalised care plan in place acerbations of heart failure or medication ges within the past 3 months					
 Recent hospital discharge Monitoring & Medicines management as per NICE guidance Complex diuretic management. 	No ex change HF Nurs on-going / QOF**	nalised care plan in place cacerbations of heart failure or medication ges within the past 3 months e will refer back to GP / practice nurse for g heart failure review as per NICE guidelines					
 Recent hospital discharge Monitoring & Medicines management as per NICE guidance Complex diuretic management. Referral to appropriate agencies / MDT / services Liaise with Consultant-led MDT- Heart Failure for 	No ex chang HF Nurs on-going / QOF**	nalised care plan in place accerbations of heart failure or medication ges within the past 3 months e will refer back to GP / practice nurse for					
 Recent hospital discharge Monitoring & Medicines management as per NICE guidance Complex diuretic management. Referral to appropriate agencies / MDT / services Liaise with Consultant-led MDT- Heart Failure for specialist advice Consideration for further interventions (CRT / 	No ex chang HF Nurs on-going / QOF**	nalised care plan in place cacerbations of heart failure or medication ges within the past 3 months e will refer back to GP / practice nurse for g heart failure review as per NICE guidelines t decompensates with HF again refer back to					

*Normal working days are Monday – Friday 9am-5pm except bank holidays

**Gp to refer housebound patients to District Nursing team / Community Matrons if required for Integrated chronic disease review for heart failure management, heart failure review as per NICE guidelines / QOF.

Note – *GP to check referral criteria for local Community HF service if commissioned.

Appendix 3: Specialist re-assessment and possible treatment options for HFrEF

ARNI (sacubitril + valsartan / Entresto®)

Sacubitril + Valsartan contains the combination of sacubitril (a neprilysin inhibitor) and the angiotensin receptor blocker valsartan. When compared with an ACEI it has been shown to improve life expectancy and reduce the likelihood of hospital admission in patients with HFrEF.

It has been approved by NICE as an alternative to ACEI in patients with symptomatic HFrEF. NICE recommend that treatment with sacubitril + valsartan should be initiated by a heart failure specialist with access to the multidisciplinary heart failure team.

Depending on blood pressure and dose of current ACEI/ARB the starting dose is 24/26mg twice a day or 49/51mg twice a day which is then titrated to the maximum tolerated dose (target dose 97/103mg twice a day.

To reduce the risk of angioedema any ACEI must be permanently discontinued at least 36 hours prior to the initiation of sacubitril + valsartan.

Any ARB (other than the valsartan in Entresto®) must be permanently discontinued but a break in treatment is not needed. Monitor renal function, electrolytes (Na+, K+) and blood pressure and for signs of angioedema (as you would for ACEI/ARB therapy).

Potassium binders

In patients where hyperkalaemia prevents introduction/optimisation of ACEI/ARB/ ARNI a potassium binder - patiromer (Veltassa®) or sodium zirconium cyclosilicate (Lokelma®) may be considered.

SGLT2 inhibitors

The SGLT2i dapagliflozin (10mg once and day) and empagliflozin (10mg once a day) are both licensed and NICE approved for use in HF with or without type 2 diabetes (avoid in type 1 diabetics) and in CKD. See the treatment pathways for HFpEF, HFmrEF and HFrEF for place in therapy.

Seek further advice if required from heart failure specialist /cardiology

Advice from a diabetes specialist may be required if the patient is on insulin (reduction in insulin dose likely needed) or any concern over diabetic management, in particular those patients on oral agents that may cause hypoglycaemia – eg sulphonylureas.

Ivabradine

Ivabradine is approved by NICE and may be considered for patients with HFrEF, NYHA II-IV symptoms, in sinus rhythm with heart rate ≥75bpm despite the maximum tolerated dose of beta-blocker licensed for heart failure.

Note: up-titration of the beta-blocker to target dose should be considered first.

Target doses of beta-blocker are bisoprolol 10mg/day, carvedilol 25mg bd (or 50mg bd if weight over 85kg) or nebivolol 10mg/day.

The dose range for ivabradine is 2.5-7.5mg twice a day.

Digoxin

Digoxin is particularly useful for rate control in heart failure patients with atrial fibrillation (AF) and may be prescribed by the Primary Care team.

It can also be used, in low dose, as an adjunct for symptomatic relief for patients in sinus rhythm. Careful dosing is required in renal impairment.

Hydralazine + Nitrate

This combination is occasionally used for patients intolerant of ACEi and ARB or in addition to ACEi/ARB in symptomatic patients. Typically doses are: hydralazine 25mg twice /three times a day up to max 75mg three times a day + isosorbide dinitrate 10-40mg bd.

Implantation of a cardiac device

Some patients may meet the criteria for device therapy. Eligibility will depend on degree of LV impairment and ECG findings based on QRS duration. An informed discussion with a specialist is required before any patient is listed for a cardiac device.

This may be cardiac resynchronisation therapy (CRT-P) an implantable cardio-defibrillator (ICD) or cardiac resynchronisation therapy + implantable cardio-defibrillator (CRT-D).

Intravenous Iron Infusion

Many heart failure patients are not anaemic but have low iron stores and there is some evidence that repletion of iron can improve patient's symptoms/quality of life. Oral iron supplements are usually ineffective.

Criteria for intravenous iron is determined by the haemoglobin level along with assessment of ferritin and total iron saturation results.

This can be offered as a day case attendance according to local pathways.

Please note if a patient is anaemic do not refer to the heart failure team for IV iron – this should be investigated in line with clinical need.

U NOVARTIS



TOP TIP

Primary Care Cardiovascular Society

Driving primary care to deliver the best in cardiovascular health

Top tips for reviewing patients with **Chronic Heart Failure in a virtual consultation**

Use these top tips to get the most out of your virtual consultations with your adult patients who have been diagnosed with chronic heart failure with reduced ejection fraction



1

Consultation preparation • What is the reason for the consultation?

- Review the patient's clinical record
- Any recent cardiac decompensation, hospitalisation or contact with the
- HE services? Have they had any recent blood tests?
- Any recent relevant investigations?

Assessment and presenting history • Have they noticed a change in ADL, increased fatigue

or change in exercise tolerance, e.g. NYHA? If exercise

Virtual examination-

practical examples

• Can the patient move around

or say a complete sentence

breathing or signs of oedema?

without being breathless? Can you observe rate of

Ask patient to go and get something from another room to observe breathing Consider asking the patient or relative to test for pitting oedema

Can the patient move the camera to

show different parts of their body?

tolerance has changed is it gradual or sudden?

• Are they breathless while lying flat or wake in the

• Have they had newly developed or worsening of

ankle swelling or increases in weight?

Have they been aware of palpitations?

night feeling breathless?



If patient doesn't have a smartphone could they borrow one (e.g. from family member or carer)?

Encourage the use of technology

- Is patient using a phone, smartphone or computer?
- Consider the use of video to enhance the consultation
- Do they have a home BP monitor? If so, record BP and pulse
- Ask questions regarding appropriate ADL e.g. have they taken the bins out?/ been gardening?/walked the dog?
- Do they have scales? If so, record weight Do they have any other co-morbidities that may affect these symptoms e.g. COPD?

Medication review

• How well is the patient managing their drugs? Are they compliant? Has their medication been optimised?



Is there a family member or carer who can give an additional perspective? Consider the use of a dosette box

Next steps

٩

TÔP

TIPS

• Following the patient assessment & examination use the information below to guide your next steps.

No cause for concern

Y



Set a next review date

Remind patient of how to identify early signs of their condition worsening and when they should be seeking advice

Seek further advice, \sim Call or refer to HF specialist team or cardiologist

- If patient's symptoms or signs have worsened, e.g. minor change in NYHA

HF= Heart failure, ADL = activity of daily living, BP = blood pressure, COPD = Chronic obstructive pulmonary disease, U&E = Urea & electrolytes, eGFR = estimated glomerular filtration rate, FBC = full blood count, ECG = electrocardiogram, NYHA = New York Heart Association This infographic has been developed and funded by Novartis. It has been produced in collaboration with


Dr Majid Akram and Dr Jim Moore. This infographic is endorsed by the Primary Care Cardiovascular Society (PCCS).

Urgent action needed

- Act immediately, e.g. seek emergency specialist advice call 999
- severe breathlessness
- NYHA class
- If patient has acute decompensation
 - NYHA symptom grading NYHA I No symptoms NYHA II Mild symptoms (e.g. walking) NYHA III - Marked limitation NYHA IV - Severe limitation (e.g. at rest)



18



This infographic has been developed and funded by Novartis. It has been produced in collaboration with

Ms Carys Barton and Dr Jim Moore. This infographic is endorsed by the Primary Care Cardiovascular Society (PCCS) and the British Society for Heart Failure (BSH).

10002-001y 2022

NYHA III - Marked limitation

NYHA IV - Severe limitation (e.g. at rest)

Primary Care Heart Failure Patient Advice Sheet

Follow up: you may be referred by your GP to be seen in the cardiology outpatient clinic or remain under your GP for ongoing management of heart failure. Some patients may also be referred to a heart failure specialist service. You will be told by your GP what follow up to expect.

Monitoring your blood pressure and pulse: you should obtain a home blood pressure monitor (HBPM), take regular readings and keep a record of your blood pressure, pulse rate, and if your pulse feels regular or irregular so you can share them with your doctor or nurse when you have a review.

Monitoring your weight: weigh yourself every morning. If your weight goes up suddenly by 2 – 4 pounds (about 1 kilo) in 2 days you could be retaining fluid.

Worsening of symptoms and self management of diuretics:

if you notice a worsening of your breathlessness, have more ankle swelling, or notice a sudden weight gain, you may need a change to your diuretic treatment. If your doctor or nurse has advised you then self manage by taking an extra diuretic for **3 days** (for example: Furosemide 20mg – 40mg tablet **OR** Bumetanide 0.5mg – 1mg tablet), or telephone your doctor or nurse to discuss. If you do self-manage for 3 days and your symptoms have not improved after 3 days then telephone your doctor or nurse for a review.

Activity: try to be as active as your condition allows. Walking is good and can be built into your daily regime. If you get breathless during exercise, you should slow down or stop.

Rest: if you have oedema (swelling) in your legs it will help when resting to elevate your legs on a footstool. If your breathing feels more difficult lying flat in bed try increasing the amount of pillows you use.

Diet: it is important to reduce the amount of salt in your diet as it can make you retain water. Do not add salt at the table and avoid cooking with it. Avoid salty foods such as Marmite, Bovril and crisps. Convenience foods are also particularly high in salt. In addition we recommend a 'healthy diet': reduce the amount of saturated fat, aim to eat at least five portions of fruit and vegetables a day, and eat fish twice a week.

Alcohol: drinking too much can sometimes make your heart failure worse so drink no more than 1 or 2 units of alcohol a day. Some patients will be advised to have none.

Medication: you will be started on a number of medicines that

will improve your symptoms and are a key part of your treatment. It is important to continue taking the medication unless instructed differently by your doctor or nurse. If you have any problems taking your medicines or getting supplies please speak to your doctor, nurse or pharmacist.

Smoking: if you smoke, stop smoking. If you would like a referral to a smoking cessation service who can support you though this process please talk to your doctor or nurse.

Vaccines: make sure you have an annual flu vaccine, Covid booster and a one-off vaccine for pneumonia.

Support: If you have any questions please ask your doctor or nurse. Further information can also be found in the <u>resource page</u> where the British Heart Foundation Heart Failure hub and the <u>Pumping</u> Marvellous Foundation hold all their resources for patients and families.

Benefits: You may be eligible to claim for Attendance Allowance which is for people over State Pension age who need help due to illness or disability. It is a nonmeans-tested tax-free weekly payment. Find out more and apply here:

Driving & transport: <u>check</u> your eligibility and apply for a blue badge here.

Heart Failure Patient – Self Management


Contact your heart failure nurse/GP if you are concerned.

If you are no longer seeing a heart failure specialist team/nurse but were discharged on the patient-initiated follow-up pathway (PIFU) you my be able to self-refer back to the service.

The symptom checker is a useful guide on what to look out for and what to do: http://qr.pumpingmarvellous.org/SymptomSM



This guide is also available in Welsh, Bengali, Polish, Punjab and Urdu.



Resources for Clinicians and Patients

British Heart Foundation

For patients:

- BHF patient support information
- British Heart Foundation: Living with heart failure booklet
- Heart Failure Matters patient information

Plus BHF helpline info:

Call* 0300 330 3311 open weekdays 9am – 5pm, Saturdays 10am – 4pm. Or email at <u>hearthelpline@bhf.org.uk</u> and BHF nurse will get back to you as soon as possible. *costs are the same as calling a home or business landline.

For healthcare professionals:

• <u>BHF professional information</u> (Not HF specific)

Pumping Marvellous Foundation

For patients:

 <u>Resources for people living with</u> <u>heart failure</u>

Contact 01772 796542 or email hearts@pumpingmarvellous.org

For healthcare professionals:

<u>NHS Teams patient information</u>
 <u>order form</u>

Cardiomyopathy UK

<u>http://www.cardiomyopathy.org</u>

Arrythmia Alliance

<u>https://heartrhythmalliance.org</u>

AF Association

https://heartrhythmalliance.org/afa/uk

NICE Guidelines

<u>NICE Chronic Heart Failure Guideline</u>
 <u>– 2018 (ng106)</u>

UCLPartners Proactive Care Frameworks

UCLPartners CVD resources

Provide a platform for optimising clinical care and self-care for people with these high-risk conditions, supporting primary care teams to do things differently and at scale. They are free and can be downloaded directly into a practices clinical system and help identify the individuals who would benefit from a review and possible referral.

The following slide packs include pathways and resources to support clinicians treating patients with single or multiple cardiovascular conditions.

- <u>Atrial Fibrillation</u>
- Heart Failure
- Hypertension
- Lipid management including Familial <u>Hypercholesterolaemia</u>
- <u>Type 2 Diabetes</u>

Primary Care Cardiovascular Society (PCCS) CVD Academy

About the academy

For clinicians:

The Academy provides PCCS members with a variety of different educational resources in cardiovascular disease. Each module is CPD accredited and you can download a certificate directly from the Academy.